Regadenoson

{{DrugProjectFormSinglePage |authorTag=

Gerald Chi

|genericName=

Regadenoson

|aOrAn=

a

|drugClass=

vasodilator

|indication=

radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress

|hasBlackBoxWarning=

|adverseReactions=

angina, dysrhythmia, chest discomfort, chest pain, tachycardia, ventricular premature complex, nausea, dizziness, headache, dyspnea, and flushing

|blackBoxWarningTitle= Title

|blackBoxWarningBody= ConditionName:

• Content

|fdaLIADAdult=

Radionuclide Myocardial Perfusion Imaging

• Lexiscan® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

• Dosing Information

• The recommended intravenous dose of Lexiscan is 5 mL (0.4 mg regadenoson)
• Administer Lexiscan as a rapid (approximately 10 seconds) injection into a peripheral vein using a 22 gauge or larger catheter or needle.
• Administer a 5 mL saline flush immediately after the injection of Lexiscan.
• Administer the radionuclide myocardial perfusion imaging agent 10–20 seconds after the saline flush. The radionuclide may be injected directly into the same catheter as Lexiscan.
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Lexiscan if it contains particulate matter or is discolored.

|offLabelAdultGuideSupport=

There is limited information regarding Off-Label Guideline-Supported Use of Regadenoson in adult patients.

|offLabelAdultNoGuideSupport=

There is limited information regarding Off-Label Non–Guideline-Supported Use of Regadenoson in adult patients.

|fdaLIADPed=

• Safety and effectiveness in pediatric patients (< 18 years of age) have not been established.

|offLabelPedGuideSupport=

There is limited information regarding Off-Label Guideline-Supported Use of Regadenoson in pediatric patients.

|offLabelPedNoGuideSupport=

There is limited information regarding Off-Label Non–Guideline-Supported Use of Regadenoson in pediatric patients.

|contraindications=

• Do not administer Lexiscan to patients with the following conditions (unless these patients have a functioning artificial pacemaker):

• Second- or third- degree AV block
• Sinus node dysfunction

|warnings=

• Description

Precautions

• Description

|clinicalTrials=

There is limited information regarding Clinical Trial Experience of Regadenoson in the drug label.

Miscellaneous

|postmarketing=

There is limited information regarding Postmarketing Experience of Regadenoson in the drug label.

Miscellaneous

|drugInteractions=

• Drug

• Description

|useInPregnancyFDA=

• Pregnancy Category

|useInPregnancyAUS=

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Regadenoson in women who are pregnant.

|useInLaborDelivery= There is no FDA guidance on use of Regadenoson during labor and delivery.

|useInNursing= There is no FDA guidance on the use of Regadenoson with respect to nursing mothers.

|useInPed= There is no FDA guidance on the use of Regadenoson with respect to pediatric patients.

|useInGeri= There is no FDA guidance on the use of Regadenoson with respect to geriatric patients.

|useInGender= There is no FDA guidance on the use of Regadenoson with respect to specific gender populations.

|useInRace= There is no FDA guidance on the use of Regadenoson with respect to specific racial populations.

|useInRenalImpair= There is no FDA guidance on the use of Regadenoson in patients with renal impairment.

|useInHepaticImpair= There is no FDA guidance on the use of Regadenoson in patients with hepatic impairment.

|useInReproPotential= There is no FDA guidance on the use of Regadenoson in women of reproductive potentials and males.

|useInImmunocomp= There is no FDA guidance one the use of Regadenoson in patients who are immunocompromised.

|administration=

• Oral

• Intravenous

|monitoring=

There is limited information regarding Monitoring of Regadenoson in the drug label.

• Description

|IVCompat=

There is limited information regarding IV Compatibility of Regadenoson in the drug label.

|overdose=

Acute Overdose

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Regadenoson in the drug label.

|drugBox=

{{Drugbox2 | Verifiedfields = changed | verifiedrevid = 413312613 | IUPAC_name = 2-{4-[(methylamino)carbonyl]- 1H-pyrazol-1-yl}adenosine | image = Regadenoson2.png | width = 300

| tradename = | Drugs.com = Multum Consumer Information | licence_US = Regadenoson | pregnancy_AU = | pregnancy_US = C | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Intravenous

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ^Y | CAS_number = 313348-27-5 | CAS_supplemental = 875148-45-1 | ATC_prefix = C01 | ATC_suffix = EB21 | ATC_supplemental = | PubChem = 219024 | DrugBank_Ref =  ^Y | DrugBank = | UNII_Ref =  ^N | UNII = 7AXV542LZ4 | KEGG_Ref =  ^Y | KEGG = D05711 | ChEMBL_Ref =  ^N | ChEMBL = 1201750

| chemical_formula = | C=15 | H=18 | N=8 | O=5 | molecular_weight = 390.354 g/mol | synonyms = 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide }}

|mechAction=

|structure=

This image is provided by the National Library of Medicine.

|PD=

There is limited information regarding Pharmacodynamics of Regadenoson in the drug label.

|PK=

There is limited information regarding Pharmacokinetics of Regadenoson in the drug label.

|nonClinToxic=

There is limited information regarding Nonclinical Toxicology of Regadenoson in the drug label.

|clinicalStudies=

There is limited information regarding Clinical Studies of Regadenoson in the drug label.

|howSupplied=

|fdaPatientInfo=

There is limited information regarding Patient Counseling Information of Regadenoson in the drug label.

|alcohol=

• Alcohol-Regadenoson interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=

• Lexiscan®

|lookAlike=

• N/A

|drugShortage= }}

{{#subobject:

 |Page Name=Regadenoson
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Regadenoson
 |Label Name=Regadenoson07.png

}}

{{#subobject:

 |Label Page=Regadenoson
 |Label Name=Regadenoson08.png

}}